TLPH Talphera, Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized fo…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
 Talphera (TLPH) Upgraded to Buy: Here's What You Should Know Talphera (TLPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | ||
 Talphera (TLPH) Q2 2026 Earnings Call Transcript NEPHRO study hits 75% enrollment with data expected by year-end. | ||
 Talphera, Inc. Q2 2026 Earnings Call Summary Moby summary of Talphera, Inc.'s Q2 2026 earnings call | ||
Talphera Inc (TLPH) (Q2 2026) Earnings Call Highlights: NEPHRO Study Enrollment Hits 75% as ... Talphera Inc (TLPH) reports $17.1M cash balance and advances toward Niyad PMA filing in H1 2027, backed by updated market research showing 200,000 annual CRRT procedures. | ||
 Talphera Q2 Earnings Call Highlights Talphera (NASDAQ:TLPH) said it had reached 75% enrollment in its NEPHRO-CRRT registrational study and remains on track to complete enrollment later in 2026, as the company prepares for a potential commercial launch of its nafamostat anticoagulant candidate for continuous renal replacement therapy, o | ||